Condition
ATTR
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Iodine124 Evuzamitide I124e
Research Leaders
5 sponsors active, led by University of Texas Southwestern Medical Center
Related Conditions
Often studied with 8 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Not Yet Recruiting1
Recruiting1
Clinical Trials (2)
Research Network
Common Treatments
- Iodine124 Evuzamitide I124e1
- Treatment Of Transthyretin Attr Amyloidosis In Observational Study Setting1
Active Sponsors
- University of Texas Southwestern Medical Center1
- ICON plc1
- Bayer1
- AstraZeneca1
- National Heart, Lung, and Blood Institute (NHLBI)1
Top Investigators
University of Texas Southwestern Medical Center
Related Conditions
- Attrvpn1
- Transthyretin Mediated Amyloidosis Attr1
- Attrcm1
- Attr Gene Mutation1
- Hattr1